Lateral Flow Assay Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Kits & Reagents, Lateral Flow Readers, and Others), By Application (Clinical Testing, Cardiac Marker Testing, Pregnancy & Fertility Testing, Veterinary Diagnostics, and Others), By Technique (Sandwich Assay, Competitive Assay, Multiplex Detection Assay), By Test Type (Lateral Flow Immunoassay v/s Nucleic Acid Lateral Flow Assay), By End User (Hospitals & Clinics, Diagnostic Laboratories, and Others), By Region and Competition, 2020-2030F

Market Overview

Global Lateral Flow Assay Market was valued at USD 9.88 billion in 2024 and is expected to reach USD 13.61 billion by 2030 with a CAGR of 5.48% during the forecast period. The global market for Lateral Flow Assay is experiencing significant growth, driven by the growing prevalence of infectious diseases such as TB, Hepatitis, and Influenza, STI along with the growing demand for point-of-care testing. Similarly, the growing adoption of new technology like lateral flow assay kits is expected to create significant growth during the forecast period. Additionally, growing geriatric populations are susceptible to different types of chronic diseases which enhance the demand for home-based testing methods, this, in turn, is expected to boost the market growth during the forecast period. This, during the 2019-2020 flu season, there were 36 million cases of influenza in the United States. The number of influenza deaths during the 2019-2020 flu season was 20,342. Most deaths attributed to influenza during the 2019-2020 flu season occurred among those aged 65 years and older.

Key Market Drivers

Growing Demand for Rapid Diagnostic Testing in Infectious Diseases

One of the primary drivers of the global lateral flow assay (LFA) market is the increasing demand for rapid and point-of-care diagnostics, especially for infectious diseases. The World Health Organization (WHO) continues to emphasize early and accessible diagnostics as a critical component in managing global health threats such as HIV, tuberculosis, malaria, and more recently, COVID-19. Lateral flow assays offer a quick, easy-to-use, and cost-effective method for detecting pathogens, especially in remote or resource-limited settings.

For example, during the COVID-19 pandemic, rapid antigen-based lateral flow tests played a vital role in large-scale population screening and outbreak management. Governments worldwide distributed millions of LFA-based COVID-19 tests to curb viral transmission. According to the U.S. Food and Drug Administration (FDA), more than 30 rapid antigen tests received Emergency Use Authorization (EUA) during the pandemic period. Similarly, the Indian Council of Medical Research (ICMR) advocated for the use of LFA kits in rural and semi-urban settings where RT-PCR infrastructure was lacking.

This growing emphasis on decentralized testing and early disease detection is also being seen in sexually transmitted infections, dengue, and hepatitis—where LFA formats offer viable alternatives to lab-based testing. As healthcare policies globally continue to pivot toward early intervention and cost containment, the adoption of lateral flow assays is expected to rise steadily in both public health systems and private care settings.

Increased Utilization in Home-Based and Self-Testing Applications

The rise of consumer-centric healthcare has significantly propelled the demand for home-based and self-testing kits, in which lateral flow assay technology is a major enabler. These tests empower individuals to monitor their health conveniently, confidentially, and without the need for laboratory support. Governments and regulatory agencies have recognized the benefits of self-testing, especially in chronic disease monitoring and reproductive health.

One prominent area is the use of LFA in pregnancy and ovulation test kits. According to the Centers for Disease Control and Prevention (CDC), nearly 62% of U.S. women of reproductive age use some form of contraception or fertility awareness, and many rely on home test kits for pregnancy confirmation and cycle tracking. Similarly, at-home tests for urinary tract infections, HIV status, and blood glucose monitoring are being developed or enhanced using LFA technology. Additionally, governments in countries like the UK and Germany have implemented national distribution schemes for home-based LFA kits during public health emergencies, further validating their utility. The convenience and non-invasiveness of these tests, combined with increasing public health awareness, make LFAs an indispensable part of the self-testing movement. These kits also reduce the burden on healthcare facilities, especially in overburdened or rural systems. As the emphasis on personal health ownership grows, the demand for LFA-based at-home testing solutions is expected to rise substantially.

Download Free Sample Report

Key Market Challenges

Quality Control and Regulatory Variability Across Regions

A persistent challenge in the LFA market is the inconsistency in quality control and regulatory standards across different countries. While agencies like the U.S. FDA and the European Medicines Agency (EMA) have clear guidelines for diagnostic device approval, many low- and middle-income countries lack robust regulatory frameworks for point-of-care testing kits. This creates disparities in product quality, patient outcomes, and market confidence. According to the WHO, many lateral flow products, especially those marketed for malaria or COVID-19 in developing countries, have shown inconsistent sensitivity and specificity. Substandard or counterfeit products not only compromise patient safety but also erode trust in rapid diagnostic solutions. These issues are exacerbated in humanitarian crises or emergency outbreaks, where the rush to supply large quantities of tests can bypass quality control mechanisms.

Moreover, some LFA kits do not meet Good Manufacturing Practice (GMP) standards, and variability in raw material sourcing—such as nitrocellulose membranes or gold nanoparticles—can affect test performance. Governments must enhance oversight, enforce post-market surveillance, and invest in laboratory evaluations to mitigate risks. Harmonizing regulatory guidelines and encouraging international collaborations (such as WHO’s Prequalification Program) can help standardize quality across borders and protect public health.

Limited Sensitivity and Detection Range in Complex Conditions

Despite their advantages, lateral flow assays often face criticism for their relatively low sensitivity and limited quantification capability compared to laboratory-based techniques such as ELISA or PCR. This can be especially problematic in detecting diseases at early stages or in conditions requiring high sensitivity—like certain cancers or low-burden infectious diseases. For instance, in tuberculosis screening, WHO has stated that traditional LFAs often miss low bacterial load cases, leading to false negatives. Similar concerns arise in HIV testing during the window period or in detecting asymptomatic carriers of viral infections. The low analytical sensitivity of some LFA kits can lead to underdiagnosis and hinder effective disease surveillance and management.

Furthermore, the development of multiplexed LFAs (capable of detecting multiple analytes) is still limited by technical challenges such as cross-reactivity, membrane saturation, and signal interference. For complex diagnostic needs, such as co-infections or biomarker panels for oncology, current LFA formats may not provide the required resolution. To address this, there is a growing need for innovation in assay design, reagent formulation, and signal amplification. Public-private partnerships and research initiatives supported by institutions such as the National Institutes of Health (NIH) or European Commission Horizon programs can help accelerate R&D to overcome these limitations.

Key Market Trends

Integration of Digital Readers and Smartphone Connectivity

A major trend shaping the lateral flow assay market is the integration of digital readers and mobile technologies. Traditional LFAs rely on visual interpretation, which can be subjective and susceptible to human error. The development of smartphone-compatible readers and dedicated apps for LFA result interpretation has significantly enhanced test accuracy, traceability, and data management. The U.S. National Institutes of Health (NIH) has supported initiatives to improve diagnostic tools with digital readouts, especially under the Rapid Acceleration of Diagnostics (RADx) program. Digital readers not only improve diagnostic confidence but also allow test results to be stored, analyzed, and transmitted securely—benefits that are especially useful in public health surveillance and epidemiology.

In low-resource settings, mobile connectivity has opened doors for real-time data collection and transmission, enhancing disease tracking and healthcare delivery. For instance, in sub-Saharan Africa, LFA tests with smartphone-enabled readers have been used to diagnose HIV and monitor antiretroviral treatment adherence. These innovations bridge the gap between point-of-care diagnostics and centralized health information systems, helping healthcare providers make faster, data-driven decisions. Furthermore, digital integration enables automated calibration, quality control, and cloud-based analytics, making LFA-based diagnostics more adaptable to telemedicine frameworks. As digital health ecosystems mature globally, the fusion of LFA platforms with technology will become a key differentiator in diagnostics.

Expansion Beyond Infectious Diseases into Chronic and Lifestyle Disorders

While lateral flow assays have historically been associated with infectious disease diagnostics, a significant trend is their expansion into chronic disease monitoring and lifestyle-related conditions. As the global burden of diseases like diabetes, cardiovascular disorders, and kidney dysfunction increases, there is a rising need for portable and cost-effective tools for early detection and ongoing monitoring. For example, according to the International Diabetes Federation (IDF), approximately 537 million adults worldwide were living with diabetes in 2021. LFAs are increasingly being developed to detect biomarkers such as glycated hemoglobin (HbA1c), microalbumin, or lipids. These tests are particularly useful in primary care settings where laboratory facilities are limited. Additionally, LFA-based cardiac marker tests (e.g., troponin I) are helping screen patients for acute myocardial infarctions in emergency care and remote health facilities.

Nutrition and wellness are also emerging application areas, with tests targeting vitamin deficiencies, food intolerances, and hormone imbalances. These innovations are being driven by consumer demand for preventive healthcare and personalized nutrition. Governments and public health agencies are also exploring LFAs for mass screening in schools and community health programs. As the scope of LFA applications broadens, the technology’s versatility and scalability are likely to redefine how chronic and lifestyle diseases are managed, particularly in underdiagnosed populations.

Segmental Insights

Product Insights

Based on Product, the Kits & Reagents segment holds the largest market share by product category. This dominance is attributed to the widespread use of lateral flow assay kits across a variety of diagnostic applications including infectious disease detection, pregnancy testing, cardiac marker monitoring, and more recently, chronic disease screening. These kits are the core component of the lateral flow technology, as they directly perform the test and deliver visual results, which makes them indispensable in both clinical and home-based diagnostic environments. Kits & reagents are consumed with every individual test, unlike readers or accessories which are reused. This high frequency of use results in significantly higher volumes of production and sales compared to hardware components like lateral flow readers. Moreover, the affordability and ease of distribution of these kits further support their large-scale deployment, especially in low-resource and remote healthcare settings. In public health emergencies like COVID-19, the demand for these consumables surged, highlighting their critical role in decentralized testing.

Download Free Sample Report

Regional Insights

Based on the region, North America holds the largest share of the global Lateral Flow Assay Market, primarily due to its well-established healthcare infrastructure, high prevalence of cardiovascular and peripheral arterial diseases, and rapid adoption of advanced medical technologies. The region benefits from strong support systems like government healthcare programs (such as Medicare and Medicaid in the U.S.), which often reimburse for minimally invasive procedures involving balloon catheters. Furthermore, the presence of leading medical device companies, research institutions, and skilled interventional cardiologists enhances the regional market dominance. Regulatory bodies like the U.S. FDA also play a crucial role in accelerating the availability of innovative catheter-based treatments, further strengthening North America’s position as a key contributor to market growth.

Recent Developments

• In January 2025, The BIOMÉRIEUX announced an agreement to acquire SpinChip Diagnostics ASA, a Norwegian diagnostics company known for its innovative immunoassay platform. This acquisition aims to bolster bioMérieux's point-of-care diagnostics capabilities
• In February 2024, The BIOMÉRIEUX entered a strategic research collaboration with the U.S. Food and Drug Administration (FDA) to develop advanced tools for detecting food-borne pathogens, including Shiga-toxin producing E. coli, Cyclospora cayetanensis, Salmonella spp., and Listeria monocytogenes.
• In March 2023, QuidelOrtho Corporation received De Novo authorization from the U.S. Food and Drug Administration (FDA) to market its Sofia 2 SARS + FIA, making it the first rapid antigen test for COVID-19 to achieve FDA market clearance.

Key Market Players

• Thermo Fisher Scientific, Inc.
• Abbott Laboratories, Inc.
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc.
• Quidel Corporation
• Hologic, Inc.
• bioMérieux SA
• PerkinElmer, Inc.
• Danaher Corporation
• QIAGEN N.V.

Report Scope:

In this report, the Global Lateral Flow Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Lateral Flow Assay Market, By Product:

o   Kits & Reagents

o   Lateral Flow Readers

o   Others

• Lateral Flow Assay Market, By Application:

o   Clinical Testing

o   Cardiac Marker Testing

o   Pregnancy & Fertility Testing

o   Veterinary Diagnostics

o   Others

• Lateral Flow Assay Market, By Technique:

o   Sandwich Assay

o   Competitive Assay

o   Multiplex Detection Assay

• Lateral Flow Assay Market, By Test Type:

o   Lateral Flow Immunoassay

o   Nucleic Acid Lateral Flow Assay

• Lateral Flow Assay Market, By End User:

o   Hospitals & Clinics

o   Diagnostic Laboratories

o   Others

• Lateral Flow Assay Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Lateral Flow Assay Market.

Available Customizations:

Global Lateral Flow Assay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Lateral Flow Assay Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]